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Dense fibrotic stroma associated with pancreatic ductal adenocarcinoma (PDAC) is a major obstacle 
for drug delivery to the tumor bed and plays a crucial role in pancreatic cancer progression. Current, 
anti-stromal therapies have failed to improve tumor response to chemotherapy and patient survival. 
Furthermore, recent studies show that stroma impedes tumor progression, and its complete ablation 
accelerates PDAC progression. In an effort to understand the molecular mechanisms associated 
with tumor-stromal interactions, using in vitro and in vivo models and PDAC patient biopsies, we 
show that the loss of miR-29 is a common phenomenon of activated pancreatic stellate cells (PSCs)/
fibroblasts, the major stromal cells responsible for fibrotic stromal reaction. Loss of miR-29 is 
correlated with a significant increase in extracellular matrix (ECM) deposition, a major component 
in PDAC stroma. Our in vitro miR-29 gain/loss-of-function studies document the role of miR-29 in 
PSC-mediated ECM stromal protein accumulation. Overexpression of miR-29 in activated stellate 
cells reduced stromal deposition, cancer cell viability, and cancer growth in co-culture. Furthermore, 
the loss of miR-29 in TGF-β1 activated PSCs is SMAD3 dependent. These results provide insights into 
the mechanistic role of miR-29 in PDAC stroma and its potential use as a therapeutic agent to target 
PDAC.
PDAC is the most lethal human cancer, with a 5-year survival rate of 6%1 and is projected to be the sec-
ond leading cause of cancer related death by 20302. Dense fibrotic stroma associated with PDAC tumors 
is a major obstacle for drug delivery to the tumor bed3,4 and plays a crucial role in pancreatic cancer 
progression5–7. Current anti-stromal therapies have failed to improve tumor response to chemotherapy 
and patient survival8, and they are often associated with toxicity9. Furthermore, recent studies show 
that the stroma impedes tumor growth, and its complete inhibition accelerated PDAC progression10,11. 
However, reprogramming the stromal reaction through modulation of a key transcriptional regulator 
in stromal cells suppressed the stromal reaction and increased tumor response to chemotherapy and 
survival12. These studies reinforce the critical need to understand the molecular mechanisms associated 
with tumor-stromal interactions for developing effective therapeutic strategies to reduce PDAC mortality.
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Stroma associated with PDAC tumors is comprised of activated stellate cells/fibroblasts, immune cells, 
extracellular matrix, and pro-inflammatory cytokines/growth factors13 (Supp Fig. 1). A dynamic interac-
tion between tumor-stromal cells and the extracellular matrix has been shown to play a critical role in 
PDAC progression13. A growing body of evidence suggests that pancreatic stellate cells (PSCs) are the 
major stromal cells responsible for fibrotic stroma. In normal pancreas, PSCs are located in periacinar 
spaces and remain quiescent. In response to pancreatic injury or carcinogenesis, PSCs are activated 
by a number of pro-inflammatory growth factors and cytokines, including transforming growth factor 
β 1 (TGF-β 1) released by cancer cells, injured acinar cells (paracrine), and activated PSCs (autocrine). 
TGF-β 1 serves as a key activator of quiescent PSCs, which is highly expressed in PDAC tumors and is 
known to play an important role in the fibrotic process associated with pancreatitis and PDAC patho-
genesis14,15. Activated PSCs are transformed into a myofibroblast-like phenotype and secrete excessive 
amounts of ECM proteins such as collagen, laminin, and fibronectin, a prominent component of PDAC 
stroma16. Extensive ECM deposition causes hypovascularity in PDAC tumors and attenuates drug deliv-
ery to the peritumoral milieu17. Furthermore, PSCs closely interact with cancer cells and the ECM to 
promote primary tumor growth and distant metastasis6,18–20. However, the molecular mechanisms asso-
ciated with stellate-cancer interactions remain poorly understood.
MicroRNAs (miRNAs) are conserved, non-coding RNAs that regulate eukaryotic gene expression and 
are critical in maintaining cellular homeostasis21. A single miRNA regulates hundreds of genes, often 
targeting multiple components of complex intracellular networks22. Thus, misregulation of an individual 
miRNA can have a profound impact on cellular physiology that leads to disease(s)23. miR-29 is known 
to play a paramount role in the fibrotic process of several organs24–28 and provides crucial functions 
downstream of pro-fibrotic signaling pathways such as TGF-β 129. Numerous functional studies have 
documented the anti-fibrotic activity of miR-29 in different tissues30, and its restored expression reduced 
fibrosis by targeting ECM proteins31, such as collagen and laminin. Additionally, a growing body of 
evidence implicates the role of miR-29 in cancer pathogenesis32 and in the tumor microenvironment33. 
The role of miR-29 in pancreatic fibrosis and PDAC tumor-stromal interactions however, has yet to be 
delineated.
Here in this study, we show that the loss of miR-29a and b is a common feature of activated PSCs and 
fibroblasts and is associated with a significant increase in stromal ECM deposition in vitro and in vivo. 
Our in vitro miR-29 gain/loss-of-function studies directly document the role of miR-29 in PSC-mediated 
stromal accumulation. In addition, overexpression of miR-29a or b in PSCs decreased stroma deposition, 
cancer cell viability, and colony growth when co-cultured with pancreatic cancer cells. Our findings show 
that miR-29 plays a critical role in regulating tumor stromal deposition and cancer growth, thus raising 
the possibility that modulation of miR-29 expression in PSCs may be therapeutically beneficial to nor-
malize the reactive stroma and enhance the efficacy of chemotherapy to target PDAC.
Results
TGF-β1 activates PSCs, downregulates miR-29, and increases ECM protein expression. In 
PDAC, activated PSCs are the major stromal cells responsible for fibrotic stroma. In an effort to evaluate 
the role of miR-29, an anti-fibrotic miRNA, in PSC-mediated stromal deposition, we challenged immor-
talized mouse PSCs and primary human PSCs with TGF-β 1, a proinflammatory growth factor that is 
associated with PDAC pathogenesis14 and that is known to activate quiescent PSCs16. Subsequently, we 
examined miR-29 family (-29a, -29b & -29c) expression in TGF-β 1 activated mouse and human PSCs 
by qPCR analysis. Both mouse and human PSCs stimulated with TGF-β 1 showed a significant loss of 
miR-29a and miR-29b compared to nascent cells, with no significant difference in miR-29c (Fig. 1a and 
Supp Fig. 2). TGF-β 1 bound TGF-β receptors (type I and type II) form an activated heterotetramer 
with serine/threonine kinase activity which phosphorylates downstream transcription factors, Smad2 
and Smad3 proteins34. Upon phosphorylation and activation, pSMAD2/3 form a heterogeneous complex 
with SMAD4, translocates into the nucleus, and directly regulates target gene expression. To verify the 
activation of TGF-β 1 signaling in PSCs, we examined the levels of its downstream effector molecules, 
pSMAD2/3. PSCs treated with TGF-β 1 showed a significant increase in pSMAD2/3 levels with no dif-
ference in total SMAD2/3 expression in both mouse and human PSCs (Fig.  1b and Supp Fig. 3). To 
further confirm TGF-β 1-mediated activation of PSCs and TGF-β 1 signaling, we evaluated the expres-
sion of α -SMA, a myofibroblast/PSC activation marker16, and connective tissue growth factor (CTGF), 
a transcriptional target and mediator for the pro-fibrotic effects of TGF-β 1. We observed a decrease in 
miR-29a and miR-29b expression (Fig.  1a) with a concurrent increase in α -SMA (Fig.  1c) and CTGF 
(Fig.  1d) expression. Upregulation of TGF-β 1 and CTGF has been well documented in human PDAC 
and chronic pancreatitis, a major risk factor for PDAC14,15,35, and causes an increase in the accumulation 
of stromal ECM proteins: collagen, laminin, and fibronectin13. Furthermore, collagen and laminin are 
direct targets of miR-2931, and fibronectin is an indirect target of miR-2926. We observed their significant 
increase in PSCs treated with TGF-β 1 in conjunction with a loss of miR-29a and miR-29b (Fig. 1e and 
Supp Fig. 4). Consistently, overexpression of miR-29 has been shown to suppress the fibrosis of various 
organs, including heart31, liver24, lung26, kidney25, and muscle27 by reducing ECM deposition.
TGF-β1 downregulates miR-29 in human fibroblasts and cancer associated fibroblasts. In 
addition to PSCs, pancreatic fibroblasts are also known to play a role in the stromal reaction associated 
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with PDAC tumors5. To understand whether the loss of miR-29 is common in TGF-β 1 activation, we 
treated normal primary human pancreatic fibroblasts with TGF-β 1 and quantified miR-29 expression 
levels. Similar to PSCs, TGF-β 1-activated primary fibroblasts had decreased miR-29a expression com-
pared to nascent cells (Fig. 2a), suggesting that the loss of miR-29a is consistent in both activated PSCs 
and fibroblasts. During PDAC initiation and progression, normal pancreatic fibroblasts convert into an 
activated state and are known as cancer associated fibroblasts (CAFs). In addition to PSCs, CAFs have 
Figure 1. TGF-β1-mediated activation of PSCs leads to downregulation of miR-29 and increases ECM 
protein expression. Mouse PSCs (mPSCs) and human PSCs (hPSCs) were serum starved for 24 hours and 
stimulated with 10 ng/ml of TGF-β 1 for 24 hours. Total RNA or protein were isolated for qPCR and western 
blot analysis respectively. (a) qPCR analysis of miR-29 family members in nascent and TGF-β 1 stimulated 
mPSCs and hPSCs. (b) Activation of pSMAD2/3 in TGF-β 1 stimulated mPSCs. Serum starved mPSCs were 
treated with TGF-β 1 for 6 hours and subjected to western blot analysis for pSMAD2/3 and total SMAD2/3 
expression. β -actin and GAPDH were used as loading controls. (c) qPCR and immunofluorescence analysis 
of PSC activation marker, alpha smooth muscle actin (α -SMA) in TGF-β 1 stimulated mPSCs. Representative 
images are shown, α -SMA (red) and nuclear stain, DAPI (blue). (d) qPCR analysis of TGF-β 1 responsive 
transcriptional gene target, connective tissue growth factor (CTGF) in nascent and TGF-β 1 stimulated 
mPSCs. (e) Western blot analysis of extracellular matrix proteins: collagen 1alpha1 (collagen 1a1), collagen 
3alpha1 (collagen 3a1), laminin gamma-1 (laminin), and fibronectin in nascent and TGF-β 1 activated 
mPSCs. α -tubulin, or GAPDH, or β -actin were used as loading controls. Relative quantification of band 
intensities, normalized to loading controls, are shown below respective blots. Experiments were repeated 3-4 
times and representative data are shown. Data is presented as the mean + standard error of the mean (SEM); 
n = 3; p-values determined by t-test, *p < 0.05, **p < 0.01.
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been shown to play a role in PDAC stromal deposition5, initiation36, progression, and metastasis37. To 
determine whether TGF-β 1 dependent loss of miR-29 is a common phenomenon in CAFs, we examined 
the effects of TGF-β 1 treatment on miR-29 expression in primary CAFs isolated from PDAC patients. 
Similarly, CAFs challenged with TGF-β 1 showed a significant decrease in the expression of miR-29 fam-
ily members (Fig. 2b), suggesting that the loss of miR-29 function is a common phenomenon of activated 
stromal cells associated with fibrotic stromal deposition.
Activation of KrasG12D in the pancreas leads to loss of miR-29 and increased collagen deposition. 
Activating mutations in the proto-oncogene KRAS are common in 90%–95% of PDAC patients, and 
KrasG12D is the most frequently found genetic aberration38. In order to explore the effects of KrasG12D on 
miR-29 expression, we collected pancreata from a well-characterized PDAC mouse model, LSL KrasG12D; 
Pdx1-Cre (KC)39, at 1–9 months of age and examined global pancreatic miR-29 expression and collagen/
connective tissue deposition. We observed a significant loss of miR-29 expression in KC mice compared 
to C57BL/6 controls (Fig.  3a) in conjunction with a significant increase in pancreatic fibrosis/collagen 
estimation by gross histopathological examination (H&E and Sirius Red stain) (Fig. 3b) and quantifica-
tion of Sirius Red positive collagen (Fig. 3c).
Global loss of miR-29 expression in human PDAC tumors. To determine the miR-29 expression 
patterns in human PDAC tumors and establish its clinical relevance, we examined miR-29 expression in 
PDAC patient biopsies with 35–80% tumor stroma, assessed via Sirius Red staining, and compared them 
to normal patient control samples. Similar to KC mice, we observed a significant decrease in all miR-29 
family members in PDAC tumor samples compared to normal patient controls (Fig. 3d). Furthermore, 
we conducted H&E and Sirius Red staining and observed a corresponding increase in fibrosis in PDAC 
tumor biopsies by both gross histopathological examination (Supp Fig. 5a) and quantification of Sirius 
Red staining (Supp Fig. 5b).
PSC and epithelial cell specific miR-29 loss of expression in KC mice and human PDAC tumors. 
As we observed global loss of miR-29 in both human PDAC tumors and KC mice, to examine PSC 
and epithelial cell specific miR-29 expression patterns in PDAC tumors and KC mice pancreata, we 
performed in situ hybridization of miR-29a, the most abundantly expressed miR-29 family member in 
PSCs, epithelial cells, and the pancreas (Supp Fig. 6). To assess PSC specific miR-29 expression, we 
co-stained PDAC tumors and KC mice pancreata with miR-29a and glial fibrillary acidic protein (GFAP), 
a cell marker of both active and inactive PSCs/fibroblasts40. Consistent with PSCs/fibroblasts challenged 
with TGF-β 1, GFAP positive cells of PDAC tumors displayed a significant loss of miR-29a compared to 
normal patient control pancreata (Fig. 4a,b). Similarly, KC mice displayed significant loss of miR-29a in 
Figure 2. TGF-β1 downregulates miR-29 in human fibroblasts and cancer associated fibroblasts. Primary 
human pancreatic fibroblasts or cancer associated fibroblasts (CAFs) isolated from human PDAC tumors 
were stimulated with 10 ng/ml of TGF-β 1 for 24 hours, and total RNA was isolated for miR-29 expression 
analysis. (a) qPCR analysis of miR-29 family members in TGF-β 1 activated primary human pancreatic 
fibroblasts or (b) PDAC CAFs (n = 3). Data is presented as the mean + SEM; n = 3; p-values determined by 
t-test, *p < 0.05, #p < 0.08, **p < 0.01. Experiments were repeated three times and representative data are 
shown.
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GFAP-positive cells compared to control mice at early (2–4 months) and late ages (9–10 months) (Supp 
Fig. 7).
To examine epithelial cell specific miR-29 expression patterns, we co-stained human PDAC tumors 
and KC mice pancreata with miR-29a, and Cytokeratin-19 (CK19), a cell marker specific to epithelial 
cells41. Similar to PSCs, CK19-positive epithelial cells of PDAC tumors (Fig. 4c,d) and KC mice (Supp 
Fig. 8) showed a significant loss of miR-29 expression compared to normal controls, indicating that the 
global loss of miR-29 may be attributed by both stromal PSCs and epithelial cells.
Physiological role of miR-29 in PSC-mediated stromal ECM protein accumulation. Since the 
loss of miR-29a/b was commonly observed in PSCs/fibroblasts challenged with TGF-β 1, in KrasG12D 
Figure 3. Global loss of miR-29 is a common phenomenon of KrasG12D activated murine pancreata and 
human PDAC tumors with increased collagen deposition. (a) miR-29 expression levels in LSL-KrasG12D; 
Pdx1-Cre (KC), PDAC mouse model. Total RNA was isolated from formalin fixed paraffin embedded (FFPE) 
pancreatic tissue sections of KC or C57BL/6 control mice (n = 3–5 animals/time point) and subjected to 
miR-29 expression analysis via qPCR. (b) Representative H&E and Sirius Red stained pancreatic sections 
from C57BL/6 control and KC mice (9 months). Acinar cells (A), Islets of Langerhans (IL), pancreatic ducts 
(D), and prominent fibrosis (F) are demonstrated in the KC animals. (c) Quantification of collagen in KC 
animals from 1–9 months of age. ImageJ was used to quantify Sirius Red positive collagen. Data is presented 
as the mean ± SEM; n = 3–5 animals/time point; (d) miR-29 expression analysis in PDAC patient tumors. 
Total RNA was isolated from FFPE sections of normal controls (n = 10) (N; solid black) or PDAC patient 
tumors (n = 15) with 35–80% stroma (T; red, green, or blue), and miR-29 expression was analyzed by qPCR. 
miR-29 family members are represented by circles (miR-29a), squares (miR-29b), and diamonds (miR-29c). 
For each group, the mean expression of miR-29 family members is indicated as horizontal lines. p-values 
determined by t-test, *p < 0.05. 
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expressing murine pancreata, and in human PDAC biopsies, we performed in vitro gain/loss-of-function 
studies to determine the physiological role of miR-29 in PSC-mediated stromal protein expression using 
synthetic miR-29 mimics and miR-29 locked nucleic acids (LNAs), a miR-29 family inhibitor. To test 
the effect of miR-29 gain-of-function on PSC-mediated stromal accumulation, we transfected mouse and 
human PSCs with control, miR-29a, or b mimics, before (data not shown) and after TGF-β 1 treatment, 
and examined ECM protein levels. We confirmed the overexpression of miR-29a and miR-29b in both 
mouse and human PSCs transfected with synthetic miR-29a/b mimics (Supp Fig. 9). As expected, we 
observed a significantly lower expression of direct miR-29 ECM protein targets (Fig. 5a) in PSCs trans-
fected with miR-29 mimics compared to cells transfected with control mimic. Interestingly, in miR-29 
overexpressed PSCs, we also saw a decrease in fibronectin, a major ECM protein in PDAC stroma and a 
known indirect target of miR-2926 (Fig. 5b and Supp Fig. 10).
In order to better understand the underlying mechanism for miR-29-mediated fibronectin repression 
in TGF-β 1 activated PSCs, we investigated the effect of miR-29 on TGF-β 1 signaling. We observed a 
decrease in pSMAD2 levels in PSCs transfected with miR-29a or miR-29b compared to control mimic 
(Fig. 5c and Supp Fig. 11), suggesting an indirect effect of miR-29 on fibronectin suppression.
For miR-29 loss-of-function studies, we transfected TGF-β 1 activated PSCs with control or miR-
29 LNAs and assessed the effects on stromal protein accumulation. We confirmed the knockdown of 
all three miR-29 family members in PSCs transfected with miR-29 LNAs (Supp Fig. 12). Inhibition of 
miR-29 by LNAs led to a further increase in accumulation of ECM proteins (Fig. 5d and Supp Fig. 13).
Ectopic expression of miR-29 in PSCs reduces stromal deposition, cancer cell viability, and 
colony growth in co-culture. Subsequently, to evaluate the effects of miR-29 overexpression in 
PSCs on cancer growth, we transfected PSCs with control or miR-29 mimics and co-cultured them with 
Figure 4. PSC and epithelial cell specific miR-29 loss of expression in human PDAC tumors. (a, c) In 
situ hybridization of miR-29 in PSCs (a) and epithelial cells (c) of normal control and PDAC patient tumors. 
FFPE pancreatic tissue sections from normal control and PDAC patients (n = 4/group) were subjected to 
miR-29a in situ hybridization. Representative images are presented as a single channel or merged (scale 
bar is 5 μm, 20X magnification). Hoechst nuclear stain (magenta), U6 (red), miR-29a (green), and GFAP-
positive PSCs or CK19-positive epithelial cells (blue). (b, d) Corrected total cell fluorescence (CTCF) of miR-
29a in PDAC tumors (n = 4) compared to control patients (n = 4) was calculated for each patient averaging 
six or more randomly selected GFAP-positive PSCs (b) or CK19-positive epithelial cells (d) using ImageJ 
analysis. Data represents mean + SEM. Statistics were generated using t-test, *p < 0.05.
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pancreatic cancer cells. Direct co-culture of PSCs overexpressing miR-29a or b with pancreatic cancer cells 
caused a significant decrease in the ability of the cancer cells to form colonies (Fig. 6a and Supp Fig. 14a) 
and reduced stromal deposition associated with cancer colonies (Supp Fig. 14b). To elucidate the under-
lying mechanism that leads to a decrease in pancreatic cancer colony formation, we evaluated the auto-
crine and paracrine effects of miR-29 on the viability of PSCs and pancreatic cancer cells, respectively. 
For autocrine effects of miR-29, we transfected PSCs with control or miR-29 mimics, and cell viability 
was monitored for up to 96 hours post-transfection. Overexpression of miR-29 did not reduce PSC via-
bility compared to cells transfected with control mimics (Supp Fig. 15). To determine the paracrine 
Figure 5. Physiological role of miR-29 in PSC-mediated stromal ECM protein accumulation. For miR-
29 gain and loss-of-function studies, serum starved and TGF-β 1 (10 ng/ml, 24 hours) treated PSCs were 
transfected with synthetic miR-29 mimics or miR-29 locked nucleic acids (LNAs), a miR-29 family inhibitor 
respectively. Subsequently, the effects of miR-29 gain and loss-of-function on extracellular matrix (EMC) 
proteins was evaluated by western blot analysis. (a) Schematic representation of the miR-29 family members, 
and 3′ -untranslated region (UTR) binding sites of miR-29 ECM targets. miR-29 encoding loci are located 
on human chromosome 7 (miR-29a/miR-29b-1) and chromosome 1 (miR-29b-2/miR-29c). All three miR-
29 family members (miR-29a, miR-29b, and miR-29c) have identical seed sequences. miR-29 binding sites 
in the 3′ -UTR of ECM protein transcripts encoding collagen 1a1 (COL1A1), collagen 3a1 (COL3A1), 
and laminin gamma-1 (LAMC1) are depicted. (b) Western blot analysis of ECM proteins in miR-29 
gain-of-function studies of hPSCs. TGF-β 1 stimulated hPSCs were transfected with 20 nM mimic control 
(ctrl), mimic-29a (29a), or mimic-29b (29b). 24 hours post-transfection, total proteins were harvested and 
subjected to western blot analysis of ECM proteins (collagen 1a1, collagen 3a1, laminin, and fibronectin). 
(c) Western blot analysis of pSMAD2 in miR-29 overexpressed hPSCs. Serum starved and TGF-β 1 treated 
hPSCs were transfected with miR-29 (20 nM) or control mimics (20 nM). 24 hours post-transfection, protein 
was harvested and subjected to western blot analysis for pSMAD2 and SMAD2. (d) Western blot analysis 
of ECM proteins (collagen 1a1, collagen 3a1, and laminin) in miR-29 loss-of-function studies of hPSCs. 
TGF-β 1 treated hPSCs were transfected with 50 nM of LNA-29 or LNA-control. 24 hours post-transfection, 
protein was harvested and subjected to western blot analysis. Relative quantification of band intensities, 
normalized to GAPDH loading control, are shown below respective blots. Each experiment was repeated 
three times and representative data are presented.
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effects of miR-29 on cancer cell viability, pancreatic cancer cells were cultured in conditioned media 
collected from PSCs transfected with control or miR-29 mimics. We observed a significant decrease in 
viability of pancreatic cancer cells growing in conditioned media collected from miR-29 transfected PSCs 
compared to PSCs transfected with control mimics (Fig.  6b and Supp Fig. 16). Finally, to evaluate the 
effect of miR-29 overexpression in PSCs on anchorage independent growth of pancreatic cancer cells, 
we co-cultured miR-29 transfected PSCs with cancer cells in soft agar assays. We observed a decrease in 
anchorage independent growth of pancreatic cancer cells when co-seeded with miR-29a overexpressing 
PSCs compared to PSCs transfected with control mimics (Supp Fig. 17). Overall, overexpression of miR-
29 in PSCs caused a decrease in stromal/ECM protein accumulation and cancer colony growth. However, 
the long-term consequences of miR-29 overexpression in stromal deposition and cancer progression 
need to be further evaluated in vivo.
TGF-β1-mediated downregulation of miR-29 in PSCs is SMAD3 dependent. We next sought 
to identify the underlying mechanism of TGF-β 1 activated loss of miR-29 in PSCs. Others have previ-
ously identified SMAD3 binding elements near the miR-29a/b-1 locus on chromosome 7 upstream of 
the miR-29a/b1 transcription start site42 (Fig.  7a). We subsequently knocked down SMAD3, a major 
downstream effector molecule of TGF-β 1, which is known to directly regulate miR-29 expression in 
myoblast and renal cells43,44 and confirmed the loss of SMAD3 protein in transfected PSCs by western 
blot analysis (Fig.  7b). PSCs transfected with control siRNA displayed a significant downregulation of 
miR-29a and miR-29b upon TGF-β 1 stimulation (Fig. 7c). Whereas in the absence of SMAD3, PSCs no 
longer showed a significant change in miR-29 (Fig. 7c), suggesting that the ability of TGF-β 1 to suppress 
Figure 6. Ectopic expression of miR-29 in PSCs reduces cancer cells viability and cancer colony 
growth in co-culture. (a) Effect of miR-29 overexpression in PSCs on cancer colony growth in direct co-
cultures. mPSCs transfected with 20 nM mimic control, mimic-29a or 29b were plated simultaneously 
with 100 pancreatic cancer cells (Panc-1) in a 6-well plate. Co-cultures were allowed to grow for 10 days, 
fixed, and stained with crystal violet fixing solution to stain cancer cells as previously described64 with 
few modifications. Cancer colonies greater than 50 cells were counted under phase contrast microscopy. 
Representative images of co-cultures stained with crystal violet are shown. (b) Conditioned media of PSCs 
expressing miR-29 show decreased effect on pancreatic cell viability. Conditioned media from mPSCs 
transfected with control, miR-29a, or miR-29b mimics was applied to pancreatic cancer cells (Panc-1) in 
a 96-well plate and viability was measured 24 and 48 hours post-treatment using the Cell Counting Kit-8 
assay according to manufacture protocol. Data is normalized to pancreatic cancer cells (Panc-1) treated with 
non-conditioned media. All experiments were repeated 3-4 times and representative data is presented. Data 
represents mean + SEM. Statistics generated by t-test, *p < 0.05, **p < 0.01.
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miR-29 expression is SMAD3 dependent. Our results, in conjunction with previous findings in muscle 
and kidney25,45 suggests that TGF-β 1-mediated loss of miR-29 in PSCs may be due to the direct binding 
of SMAD3 to miR-29 promoter elements.
Discussion
Dense, fibrotic stroma is a histopathological hallmark of pancreatic cancer, and it precludes drug delivery 
to the tumor bed3,4. Activated PSCs are major contributors of fibrotic stromal reaction and are known 
to interact with cancer cells and promote PDAC tumor progression6,7. Quiescent PSCs normally located 
within the periacinar/ductal regions of the pancreas are activated in response to autocrine and paracrine 
pro-inflammatory cytokines/growth factors and secrete excessive amount of ECM proteins, a major com-
ponent of PDAC stroma16. TGF-β 1 is a pro-tumorigenic/fibrotic growth factor secreted from cancer cells 
and injured acinar cells and is known to be a vital contributor of PSCs activation16,18. The upregulation 
of TGF-β 1 in PDAC has been well documented and perpetuates the stromal reaction13,14.
Although previous studies have shown that miR-29 is reduced in TGF-β 1 signaling and promotes 
fibrosis of various organs43,44, the role of miR-29 in the context of PSCs and PDAC fibrotic stroma has 
yet to be elucidated. In our study, we show for the first time that TGF-β 1 acts as a negative regulator of 
Figure 7. TGF-β1-mediated downregulation of miR-29 expression in PSCs is SMAD3 dependent. (a) 
Predicted SMAD3 binding sites upstream of miR-29a/b1 promoter: there are two SMAD3 binding elements 
(S3BE) 5 kb and 49 kb upstream of the transcription start site of the miR-29a/b1 loci on chromosome 7. 
SMAD3 binds specifically to CAGA boxes: AG(C/A)CAGACA and regulates neighboring gene expression. 
(b) siSMAD3 efficiently reduces endogenous SMAD3 protein levels in hPSCs. hPSCs growing in culture 
were transfected with 50 nM non-targeting siRNA (siCTRL) or siSMAD3. 24 hours post-transfection, 
total proteins were harvested and subjected to western blot analysis to determine SMAD3 expression 
levels. GAPDH was used as a loading control. (c) SMAD3 knockdown abrogates TGF-β 1-mediated miR-
29 repression. qPCR analysis of miR-29 levels in TGF-β 1-activated hPSCs transfected with siCTRL and 
siSMAD3. hPSCs were transfected with 50 nM siCTRL or siSMAD3. 24 hours post-transfection, cells 
were challenged with 10 ng/ml TGF-β 1 for 24 hours and subjected to qPCR for miR-29 expression levels. 
All experiments were repeated three times and representative data is presented. Data are presented as 
mean + SEM; n = 3, statistics generated by t-test, *p < 0.05.
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miR-29 in PSCs, while simultaneously upregulating ECM proteins: collagens, laminin, and fibronectin. 
Through qPCR analysis, we observed a predominant downregulation of miR-29a and miR-29b family 
members in both mouse and human PSCs upon TGF-β 1-mediated activation. In muscle and kidney 
fibrosis, TGF-β 1 is known to downregulate miR-29 expression in myoblasts43 and renal cells44 through 
SMAD3 binding elements located upstream of miR-29 promoter region and promote fibrosis. Similarly, 
we found that TGF-β 1-mediated miR-29 repression in PSCs is SMAD3 dependent. In addition to PSCs, 
TGF-β 1 activated pancreatic fibroblasts5 (additional stromal cells responsible for stromal reaction), also 
displayed a loss of miR-29. Interestingly, we found the downregulation of all three miR-29 family mem-
bers in TGF-β 1 stimulated CAFs isolated from PDAC patient tumors. miR-29 family members encoding 
genes reside on two different human chromosomes with miR-29a/b1 loci on Chromosome 7 and the 
miR-29c/b2 loci on Chromosome 1 (Fig. 5a)42, lending to the possibility that TGF-β 1 may elicit down-
stream effects to inhibit both miR-29 encoding loci in CAFs but not in PSCs and normal pancreatic 
fibroblasts. Our findings implicate a differential effect of TGF-β 1 in regulation of miR-29 expression in 
CAFs compared to PSCs/pancreatic fibroblasts that warrants further studies and may reveal differential 
regulatory mechanisms between miR-29 family members.
Subsequent investigation of miR-29 expression patterns in the pancreata of spontaneous tumor form-
ing PDAC mouse model carrying initiating oncogene KrasG12D (KC)39 and in PDAC patient tumor biop-
sies revealed similar findings of miR-29 loss of expression. We found a global decrease in expression of 
all three miR-29 family members in KrasG12D murine pancreata and human PDAC in conjunction with 
an increase in pancreatic fibrosis and stromal deposition associated with PDAC tumors. Although we 
observed a global loss of miR-29, these findings did not implicate whether the loss of miR-29 is specific to 
PSCs and epithelial cells associated with murine and human PDAC. Thus, we performed in situ hybridi-
zation to assess PSC and epithelial cell specific miR-29a expression by co-staining KC mice pancreata and 
human PDAC tumors with GFAP, a marker specific to PSCs/fibroblasts40 and CK19, a marker specific to 
epithelial cells41. Accordingly, we found a similar loss of miR-29a in PSCs of KC mice and PDAC patient 
samples. These findings further confirm that the loss of miR-29 is consistent in PSCs associated with 
PDAC stromal reaction. Nevertheless, our results do not document the underlying mechanisms for the 
loss of miR-29 expression in K-RasG12D activated murine pancreata and human PDAC tumors, but our 
findings advocate for future functional studies in vivo to examine miR-29 expression patterns in disease 
onset and progression in various etiologies associated with human PDAC.
Stromal ECM proteins such as collagens and laminin are direct miR-29 targets. These proteins in 
addition to fibronectin, another stromal abundant protein, interact with cancer cells and enhance tumor 
progression of various malignancies46,47 including pancreatic cancer48. Although miR-29 has been shown 
to suppress fibrosis of several different organs, including heart34, liver24, lung26, kidney25, and muscle30 
by negatively regulating ECM protein expression, the function of miR-29 in PSC-mediated ECM protein 
expression has yet to be validated. Using miR-29 gain and loss-of-function studies, we found that miR-29 
suppresses its direct ECM targets collagen1a1, collagen 3a1, and laminin in activated PSCs. Surprisingly, 
we also found that miR-29 inhibits fibronectin expression, even though fibronectin does not contain 
canonical miR-29 binding sites within its 3′ -untranslated region (Targetscan, miRanda, and PicTar). 
As a result, we sought to find an indirect mechanism for miR-29-mediated fibronectin inhibition in 
TGF-β 1 activated PSCs. Interestingly, we found that ectopic expression of miR-29 in TGF-β 1 activated 
PSCs reduced SMAD2 phosphorylation, implicating that miR-29 may act as an auto-inhibitory feedback 
regulator within TGF-β 1 signaling. TGF-β 1 is known to play a key role in PDAC pathogenesis, and its 
upregulation has been well documented in PDAC14 and pancreatitis15, a major risk factor of PDAC. 
As a consequence, TGF-β 1 has emerged as an appealing therapeutic target, and numerous therapeutic 
strategies have been developed to inhibit TGF-β 1 signaling via ligand inhibition and ligand/receptor 
interactions49. Our findings reveal miR-29 to be a potential downstream inhibitor of TGF-β 1 signaling.
In addition to the fibrotic stromal reaction, PSCs are known to interact with pancreatic cancer cells 
and promote tumor progression and metastasis. In our functional studies, restored expression of miR-29 
in PSCs caused a decrease in cancer colony growth and stromal protein accumulation associated with 
co-cultures. Our data suggests that miR-29 overexpression reduced cancer colony growth by inhibiting 
the paracrine effects of PSCs on cancer cells, as we observed a decrease in pancreatic cancer cell via-
bility. Admittedly, the precise mechanism associated with the paracrine effect of miR-29 overexpression 
in PSCs on cancer cell growth has yet to be elucidated, and future studies would further shed light on 
the role of miR-29 in tumor-stromal interactions. A large body of experimental evidence documents 
the role of extracellular matrix proteins such as collagen and laminin in cancer cell proliferation and 
drug resistance50–52. Although we observed that the overexpression of miR-29 in PSCs reduced stromal 
accumulation associated with cancer colonies, additional studies are required to elucidate the direct 
mechanistic role of miR-29 in ECM-mediated pancreatic cancer progression.
As fibrotic stroma impairs the efficacy of chemotherapeutics and promotes PDAC progression, it 
is considered as an attractive therapeutic target in developing effective treatment strategies to target 
PDAC. Current, anti-stromal therapies to date have sought to deplete the reactive stroma. However, 
these approaches failed to improve patient survival and are often associated with toxicity. Furthermore, 
recent studies show that stroma impedes tumor growth, and its complete inhibition accelerated disease 
progression10,11. However, inactivating PSCs by modulation of a key transcriptional regulator suppressed 
the reactive stroma, increased tumor response to chemotherapy and survival12. This evidence suggests 
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that normalizing reactive stroma is a safe and efficacious treatment strategy, as opposed to completely 
ablating the reactive stroma.
In our studies using in vitro and in vivo models and PDAC patient biopsies, we observed a loss of 
miR-29 in PSCs and fibroblasts, the critical stromal cells responsible for fibrotic stroma. Restored expres-
sion of miR-29 in PSCs suppressed major stromal protein expression (collagens, laminin and fibronectin) 
and inhibited cancer cell growth in co-culture. While the long-term consequences of miR-29 overex-
pression or miR-29 loss-of-function on PDAC progression/metastasis and its role in cancer cells and 
the tumor microenvironment remain to be investigated in vivo, our findings indicate that the efficacy of 
stroma-targeted therapy in PDAC may also be dictated by stromal miRNA expression and function. We 
anticipate that the restored expression of miR-29 in stromal cells reduces the stromal protein accumula-
tion and cancer growth and enhances the drug delivery to the inner tumor core. Furthermore, increas-
ing evidence indicate miR-29 plays a vital role in cancer pathogenesis32, tumor microenvironment, and 
metastasis33. In contrast to pharmacological approaches, the use of miR-29 as a therapeutic agent may be 
more effective in targeting reactive stroma, as a single miRNA regulates the expression of several genes 
associated with disease mechanisms23. Thus, restored expression of a critical miRNA is therapeutically 
beneficial and targets multiple cellular pathways associated with disease processes. In our previous work, 
we demonstrated that the replacement of a single missing miRNA suppressed tumor progression with 
no toxicity and off-target effects53.
Thus far, no studies have interrogated the relevance of miR-29 in the context of PDAC stroma. Based 
on our in vitro, in vivo, and clinical observations in stromal cells and functional studies, our results indi-
cate that miR-29 plays a critical role in stromal deposition and inhibits the pro-growth effects of PSCs 
on pancreatic cancer colony formation. Our findings raise the possibility that miR-29 could serve as an 
anti-stromal therapeutic agent in the context of PDAC. A large body of evidence demonstrates the plei-
otropic role of miRNAs in fibrotic process, cancer pathogenesis and metastasis, and their potential use as 
therapeutic agents for cancer53–55, fibrosis56, and other human diseases57. Some miRNA-based drugs have 
already reached clinical trials57,58 or are in advanced stage of pre-clinical development59,60, indicating the 
feasibility of miR-29 in prospective clinical applications. This new and substantially different approach 
is expected to overcome the problems associated with other means of modulating the stroma and result 
in an effective approach to improve drug delivery to the tumor bed. Future work aimed at determining 
the role of miR-29 in pancreatic cancer cells, patient survival, and its biological functions in vivo will 
allow us to further understand the role of miR-29 in PDAC development and progression and ultimately 
determine its prognostic and therapeutic applicability to target PDAC.
Methods
Mice. KrasG12D; Pdx1-Cre (KC) mice were generated as described39. Conditional LSL-KrasG12D mice 
were crossed with Pdx1-Cre animals to generate the KC mice. All animal housing, use, and surgical 
procedures were carried out in accordance with the regulatory guidelines set by Guide for the Care and 
Use of Laboratory Animals of the National Institutes of Health. All animal protocols were reviewed and 
approved by the Indiana University (IU) Animal Care and Use Committee.
Cell lines. Immortalized mouse pancreatic stellate (mPSC) cell lines61 were a kind gift from Dr. Raul 
Urrutia at Mayo Clinic, Rochester, Minnesota. Primary human PSCs were obtained from ScienCell 
Research Laboratories (Carlsbad, California), grown routinely in Dulbecco’s Modified Eagle Medium 
(DMEM) (Life Technologies, 11965-092) supplemented with 10% fetal bovine serum (FBS), 100 units 
ml−1 penicillin, and 100 mg ml−1 streptomycin. Primary human fibroblasts were purchased from Vitra 
Biopharma (Golden, CO), and were routinely cultured in their recommended media (VitroPlusII). 
Primary cancer associated fibroblasts (CAFs) isolated from PDAC patients were confirmed by α -SMA 
staining and authentication was performed by IDEXX-Radil (Columbia, MO). CAFs were maintained 
in DMEM/F-12, GlutaMAX Supplement (Life Technologies, 10565-018) plus 10% FBS, 100 units ml−1 
penicillin, and 100 mg ml−1 streptomycin. All primary cell lines were studied prior to reaching seven 
passages. Human pancreatic carcinoma cell lines Panc-1 and MIA PaCa-2 were kind gifts from Karen E. 
Pollok of Indiana University School of Medicine and IU Simon Cancer Center. Both were grown rou-
tinely in DMEM supplemented with 10% FBS, 100 units ml−1 penicillin, and 100 mg ml−1 streptomycin.
Patient Tissue Procurement. This study was reviewed and approved by the Indiana University-Purdue 
University Indianapolis (IUPUI) Institutional Review Board (IRB) at Indianapolis, IN, USA (IUPUI 
IRB# 1303011057). Tissue biopsies and associated clinical data were obtained from IU Simon Cancer 
Tissue Bank and IU Department of Pathology. Both IU Simon Cancer Tissue Bank and IU Department 
of Pathology procured tissue samples and informed consent was obtained from human subjects in com-
pliance with IUPUI IRB policies. IUPUI IRB is accredited by the Association for the Accreditation of 
Human Research Protection Programs (AAHRPP). Quality and integrity of paraffin embedded or fresh 
pancreatic tissue biopsies were analyzed by a certified pathologist with hematoxylin and eosin staining. 
Control samples that were biopsied from patients with conditions unrelated to pancreatic disease or 
from an unaffected area of the pancreas from patients with pancreatitis were confirmed via histopatho-
logical analysis. Corresponding patient clinical data of each sample is provided in the Supplementary 
Information (Supp Table 1 and Table 2).
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RNA Extractions. Total RNA was extracted from formalin fixed paraffin embedded (FFPE) tissue 
samples (two 10 μ m thick sections) using the MagMaxTM FFPE total nucleic acid isolation kit (Ambion, 
Life Technologies, 4463365) or from frozen tissues using Rino Bullet Blender beads (MidSci, CAP329) 
followed by Trizol (Life Technologies, 15596018) extraction. RNA was extracted from cells in vitro by 
Trizol extraction according to the manufacturer’s protocols. The quantity and purity of RNA was deter-
mined by OD260/280 reading using a Nanodrop spectrophotometer.
qPCR analysis. Mature miR-29 family member expression levels were measured by TaqMan MicroRNA 
Assays (Applied Biosystems) for miR-29a (ID:002112); miR-29b (ID:000413); and miR-29c (ID:000587). 
U6 snRNA (ID:001973) was used as a reference gene to normalize the relative amount of miRNA, and 
samples were analyzed using ABI 7500 real time PCR machine. Alpha smooth muscle actin (α -SMA), 
connective tissue growth factor (CTGF), collagen 1a1 (COL1A1), laminin (LAMC1), and fibronectin 
(FN1) levels were measured using gene specific qPCR primer probes purchased from Solaris Probes. 
RNA samples were reverse transcribed using random primers, and α -SMA (AX-061937-00-0100); CTGF 
(AX-040018-00-0100); COL1A1 (AX-042068-00-0100); LAMC1 (AX-043874-00-0100); and FN1 (AX-
043446-00-0100) expression levels were measured using cyclophilin B (PPIB) (AX-048843-00-0100) as 
an internal control. Samples were run in triplicates with 0.2 thresholds, and the Δ Δ CT method was 
used for relative expression analysis. For miR-29 expression analysis in PDAC patient tumors, total RNA 
was isolated from FFPE tissue sections (two 10 μ m) of normal controls (n = 10) or PDAC patient tumors 
(n = 15) with 35–80% stroma and miR-29 family expression was analyzed by qPCR as described above.
Immunoblotting. mPSCs and hPSCs were lysed in lysis buffer (50 mM HEPES, 150 mM NaCl, 10% 
glycerol, 1% Triton-X, 1.5 mM MgCl2, 1 mM EGTA, 100 mM NaF, 10 mM NaPPi, Na O Vanidate, ZnCl2, 
PMSF, protease inhibitor) and protein samples were ran through SDS-PAGE. Proteins were transferred to 
polyvinylidene fluoride membrane (PVDF), blocked in 10% dried non-fat milk, and subsequently probed 
with antibodies against collagen 1alpha1 (Santa Cruz, sc-8784-R, 1:500), collagen 3alpha1 (Santa Cruz, 
sc-8781, 1:500), laminin gamma-1 (Santa Cruz, sc-5584, 1:5000), fibronectin (Santa Cruz, sc-9068, 1:500), 
α -tubulin (Calbiochem, CP06, 1:3000), GAPDH (Millipore, MAB374, 1:10,000), and β -actin (Santa 
Cruz, sc-47778, 1:2000), using corresponding HRP conjugated goat anti-rabbit (Santa Cruz, sc-2004), 
goat anti-mouse (Santa Cruz, sc-2005), or donkey anti-goat (Santa Cruz, sc-2020) secondary antibodies. 
Proteins were visualized and quantified using chemiluminescent detection (GE Healthcare, Amersham 
ECL) and exposure to x-ray film (Thermo Scientific, CL-X Posure Film). The intensity for each band was 
densitometrically quantified and normalized against loading control using ImageJ software.
Transfection. Exponentially growing mPSCs or hPSCs were seeded in 6 well plates at 1 × 105 cells per 
well, serum starved for 24 hours, and treated with 10 ng/ml of TGF-β 1 for 24 hours before or after trans-
fection with 20 nM mimics using DharmaFECT® 1 (Life Technologies, T-2001-01) per their protocol. For 
immunoblotting, cells were either transfected with 20 nM mimic control (Life Technologies, CN-001000-
01), mimic-29a (Life Technologies, C-300520-05), or mimic-29b (Life Technologies, C-300520-05). For 
LNA transfection, 1 × 105 serum starved and TGF-β 1 treated hPSCs were transfected with 50 nM of LNA-
29 (Exiqon, 450039) or LNA-control (Exiqon, 199006) using DharmaFECT®1. 24 hours post-transfection, 
protein was harvested and subjected to western blot analysis. For studies involving siSMAD3, 1 × 105 
hPSCs/well (6-well plate) growing in culture were transfected with 50 nM non-targeting siRNA con-
trol (Life Technologies, D-001810-01-05) or siSMAD3 (Life Technologies, L-020067-00-005) using 
DharmaFECT®1 to inhibit endogenous SMAD3 levels in PSCs. 24 hours post-transfection, total proteins 
were harvested and subjected to western blot analysis to verify SMAD3 knockdown efficiency. For miR-
29 expression analysis in TGF-β 1-activated hPSCs transfected with siCTRL and siSMAD3, hPSCs were 
transfected with 50 nM siCTRL or siSMAD3 as described. 24 hours post-transfection, cells were serum 
starved for 24 hours, challenged with 10 ng/ml of TGF-β 1 for 24 hours, and subjected to Trizol RNA 
isolation. miR-29 expression levels were analyzed via qPCR as described above.
Co-culture. 1 × 105 mPSCs were transfected with either 20 nM mimic control, 20 nM mimic-29a, or 
20 nM mimic-29b and plated simultaneously with 100 pancreatic cancer cells (MIA PaCa2 or Panc-1) 
in a 6 well plate. Co-cultures were allowed to grow for 10 days, and were fixed and stained with crystal 
violet solution (0.05% w/v crystal violet, 1% formaldehyde, 1x PBS, 1% MeOH) or Sirius Red. Cancer 
colonies greater than 50 cells were counted under phase contrast microscopy.
Collection of PSC Conditioned Media. To obtain miR-29 and control mimic transfected PSC con-
ditioned media, exponentially growing mPSCs were seeded in a 6 well plates at 1 × 105 cells per well, 
serum starved for 24 hours, and treated with 10 ng/ml of TGF-β 1 for 24 hours before transfection with 
20 nM control or miR-29 mimics using DharmaFECT® 1 per their protocol. 24 hours post-transfection, 
cells were washed twice with PBS and incubated with DMEM with 0.2% BSA for 48 hours at 37 °C. 
Conditioned media was collected from PSCs and centrifuged at 1500 rpm for 10 min at 4 °C. Supernatant 
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was collected and then filtered using a 0.22 μ m sterile filter (Fisher Scientific, 09-719A). In parallel, 
non-conditioned media control was collected from a 6 well plates with no PSCs.
Cell Viability. 1,000 PSCs were plated per well in a 96 well plate. Cells were serum starved for 
24 hours, and treated with 10 ng/ml of TGF-β 1 for 24 hours before transfection with 20 nM control or 
miR-29 mimics using DharmaFECT® 1 per their protocol. Cell viability was measured at 24, 48, 72, 
and 96 hours after plating the assays by adding 10 ul Cell Counting Kit-8 (Dojindo #CK04) reagent and 
absorbance was measured at 450 nm. For cancer cell viability, 5,000 pancreatic cancer cells (MIA PaCa-2 
or Panc-1) were plated per well in a 96-well plate. Cancer cells were washed with PBS, and treated with 
PSC conditioned media for 24 and 48 hours. Cell viability was measured post-treatment by adding 10 ul 
of Cell Counting Kit-8 reagent and absorbance was measured at 450 nm.
Soft agar assays. 24 hours post-transfection with 20 nM control or miR-29 mimics, 50,000 mPSCs 
were co-seeded with 5,000 pancreatic cancer cells (MIA PaCa-2 or Panc-1) per well in a 6 well plate 
containing 0.5% top agarose and 1% bottom agarose (BioRad, #162-0137). After 7 days, colonies were 
stained with crystal violet and were counted under low power for positive colonies (> 6 cells/colony).
Histology. FFPE pancreata of KC and C57BL/6 mice or normal control and PDAC patients were 
sectioned (5 μ m) and stained with H&E for gross histological analysis. Tissue sections were also stained 
with Sirius Red to estimate collagen and the degree of fibrosis. ImageJ analysis was used to quantify Sirius 
Red positive collagen area in the pancreatic sections (four 20X random images/animal).
Immunofluorescence. 1 × 105 mouse PSCs, human PSCs or primary human fibroblasts were plated 
on collagen coated cover slips in 6-well plates and grown to ~80% confluency. Cells were washed with 
PBS, fixed in 4% paraformaldehyde at 37 °C and then permeabilized with 0.25% Tween-20 in PBS (PBST). 
Subsequently, cells were blocked with 1% BSA in PBS-T at room temperature and α -SMA primary 
antibody (α -SMA, Novus Biologicals, NB600-531, 1:500) and secondary antibody (Goat-α -Rabbit-594, 
Molecular Probes, 11012, 1:500) were used to detect intracellular α -SMA levels. Slides were coversliped 
using VectaShield mounting medium with DAPI (H-1200).
In Situ Hybridization. FFPE pancreata of C57BL/6 control mice at 2 and 10 months (n = 3/group) 
and KC mice at 1, 4, and 9 months (n = 3/group) were sectioned and subjected to in situ hybridization as 
previously described62. FFPE pancreatic tissue sections (5 μ m) from normal control and PDAC patients 
(n = 4/group) were also subjected to miR-29 in situ hybridization as described. Slides were hybridized 
with 50 nM 5′ -biotin labeled U6 snRNA LNA probe (Exiqon, 99002-03) and 5′ and 3′ DIG labeled miR-
29a LNA probe (Exiqon, 10000-899999-15) for 90 minutes at 55 °C. Subsequently, slides were probed 
with GFAP (Novus Biologic, NB300-141, 1:200) or CK19 antibody (Abcam, ab52625, 1:200) and stained 
with secondary antibodies conjugated to HRP to facilitate Tyramide signal amplification (TSA) reaction: 
goat anti-rabbit IgG (Santa Cruz, sc-2004, 1:500–1:1000), anti-Dioxigenin (Abcam, ab6212, 1:200), and 
Streptavadin (Thermo Scientific, #21130, 1:5000). Slides were then stained with Hoechst NucRedTM Dead 
647 (Life Technologies, #R37113) to stain nuclei. 20X images were taken using DeltaVision Core confocal 
microscope, projected in four channels, pseudo-colored, and merged. Corrected total cell fluorescence 
(CTCF) of miR-29a (green) was quantified in six or more randomly selected GFAP-positive PSCs/fibro-
blasts or CK19-positive epithelial cells using ImageJ analysis as previously described63.
Statistical analysis. Student’s t-test was used for statistical analysis. Data is presented as mean and 
error bars are represented as standard error of the mean.
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